CRVS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Corvus Pharmaceuticals Inc

NASDAQ | CRVS

8.90

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 14, 2025)

$597.46M

Market Cap

-

P/E Ratio

-0.54

EPS

$9.55

52 Week High

$2.54

52 Week Low

HEALTHCARE

Sector

CRVS Chart

Recent Chart
Price Action

CRVS Technicals

Tags:

CRVS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$85K
Total Revenue $0
Cost Of Revenue $85K
Costof Goods And Services Sold $85K
Operating Income -$28M
Selling General And Administrative $8.2M
Research And Development $19M
Operating Expenses $28M
Investment Income Net -
Net Interest Income $1.8M
Interest Income $1.8M
Interest Expense $1.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $85K
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$62M

Revenue & Profitability

Earnings Performance

CRVS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $69M
Total Current Assets $54M
Cash And Cash Equivalents At Carrying Value $8.7M
Cash And Short Term Investments $8.7M
Inventory -
Current Net Receivables $216K
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $13M
Short Term Investments $43M
Other Current Assets $2.2M
Other Non Current Assets -
Total Liabilities $36M
Total Current Liabilities $35M
Current Accounts Payable $2.6M
Deferred Revenue -
Current Debt -
Short Term Debt $185K
Total Non Current Liabilities $937K
Capital Lease Obligations $1.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.1M
Other Current Liabilities $33M
Other Non Current Liabilities -
Total Shareholder Equity $33M
Treasury Stock -
Retained Earnings -$397M
Common Stock $7K
Common Stock Shares Outstanding $61M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$25M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $85K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$27M
Cashflow From Financing $49M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$62M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$85K
Total Revenue $0
Cost Of Revenue $85K
Costof Goods And Services Sold $85K
Operating Income -$28M
Selling General And Administrative $8.2M
Research And Development $19M
Operating Expenses $28M
Investment Income Net -
Net Interest Income $1.8M
Interest Income $1.8M
Interest Expense $1.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $85K
Income Before Tax -$62M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$62M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$62M

CRVS News

CRVS Profile

Corvus Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Burlingame, California, specializing in the development of innovative immuno-oncology therapies targeting multiple cancers. The company is advancing a robust pipeline of proprietary drug candidates designed to optimize immune system responses and enhance patient outcomes through precision medicine. By fostering strategic partnerships and leveraging cutting-edge research, Corvus is actively contributing to the transformation of cancer treatment, positioning itself as a key player in the evolving oncology landscape.

WTO
+16.50%
$0.02
LPTX
+368.57%
$2.05
ASBP
+4.08%
$0.10
AMZE
+10.32%
$0.44
EPWK
+13.15%
$0.04
VHAI
-25.00%
$0.00
ONDS
+12.65%
$7.39
NVDA
+1.66%
$189.97
IVVD
+35.02%
$2.39
BYND
+11.89%
$1.13
ASST
-1.74%
$1.12
TSLA
+1.29%
$407.19
SOFI
+0.47%
$28.52
NVVE
-48.19%
$0.24
AXDX
-61.36%
$0.03
ACHR
+0.18%
$7.97
BITF
-0.96%
$2.57
PLUG
-6.73%
$2.32
ETHD
-1.77%
$5.04
PFE
-2.90%
$25.04
F
-0.33%
$13.23
PLTR
+2.15%
$175.85
RGTI
+2.21%
$25.75
INTC
-1.04%
$35.53
CHR
+3.90%
$0.04
ADAP
-15.14%
$0.05
AAPL
-0.19%
$272.95
TLRY
-3.49%
$1.09
IONZ
-9.85%
$5.11
CRWV
+0.54%
$78.77
QBTS
+2.47%
$23.96
NIO
-0.96%
$6.18
CIFR
+1.64%
$15.17
SNAP
-0.23%
$8.56
IREN
-2.77%
$47.30
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
DNN
+0.80%
$2.51
ADD
-25.47%
$0.05
AMD
+0.40%
$248.97
DVLT
+14.27%
$1.75
SMCI
-7.43%
$35.09
WULF
-1.34%
$11.52
RIVN
-7.20%
$15.20
BMNR
-7.79%
$33.72
SRM
+53.27%
$10.30
MARA
-3.87%
$12.28
CRCL
+0.72%
$82.93
WBD
+3.74%
$22.97
APLT
-8.00%
$0.24
CLSK
-6.87%
$11.15
APLD
-12.68%
$23.06
ORCL
+4.04%
$226.37
GRAB
-1.88%
$5.43
CAN
-7.35%
$0.89
BTG
+0.73%
$4.13
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
MU
+5.42%
$249.80
PLTD
-2.10%
$6.76
XPON
-5.51%
$1.20
HOOD
+1.81%
$123.73
QUBT
+5.44%
$10.57
GPUS
-5.51%
$0.28
BBD
+1.09%
$3.70
PLTZ
-4.66%
$6.71
AMZN
-0.80%
$235.67
HIMS
+3.73%
$37.39
NBIS
-5.56%
$83.70
CSCO
+1.27%
$78.36
ABEV
+1.38%
$2.55
BABA
-4.50%
$152.64
KDLY
-6.80%
$0.62
NOK
-0.51%
$6.74
T
-0.64%
$25.58
IONQ
+4.93%
$47.64
SOUN
+0.12%
$12.23
AFMD
-34.94%
$0.18
BTBT
-2.92%
$2.44
RGTZ
-3.43%
$27.17
JD
-4.50%
$29.32
RIG
+0.37%
$4.02
GOOGL
-0.35%
$277.58
BURU
-1.60%
$0.25
RIOT
+2.83%
$14.27
DEFT
-12.06%
$1.27
BAC
-0.14%
$52.79
BTE
-0.47%
$3.12
BCG
+32.28%
$1.88
QS
+1.14%
$13.72
DFLI
+6.85%
$0.82
AAL
-1.91%
$12.81
RXRX
-2.23%
$4.23
PCG
-0.95%
$16.65
LYFT
-3.13%
$23.80
BE
+8.23%
$112.07
LAES
-7.21%
$4.51
VZ
-0.06%
$41.08
PSNY
-14.57%
$0.53
KLG
-9.05%
$13.35
WTO
+16.50%
$0.02
LPTX
+368.57%
$2.05
ASBP
+4.08%
$0.10
AMZE
+10.32%
$0.44
EPWK
+13.15%
$0.04
VHAI
-25.00%
$0.00
ONDS
+12.65%
$7.39
NVDA
+1.66%
$189.97
IVVD
+35.02%
$2.39
BYND
+11.89%
$1.13
ASST
-1.74%
$1.12
TSLA
+1.29%
$407.19
SOFI
+0.47%
$28.52
NVVE
-48.19%
$0.24
AXDX
-61.36%
$0.03
ACHR
+0.18%
$7.97
BITF
-0.96%
$2.57
PLUG
-6.73%
$2.32
ETHD
-1.77%
$5.04
PFE
-2.90%
$25.04
F
-0.33%
$13.23
PLTR
+2.15%
$175.85
RGTI
+2.21%
$25.75
INTC
-1.04%
$35.53
CHR
+3.90%
$0.04
ADAP
-15.14%
$0.05
AAPL
-0.19%
$272.95
TLRY
-3.49%
$1.09
IONZ
-9.85%
$5.11
CRWV
+0.54%
$78.77
QBTS
+2.47%
$23.96
NIO
-0.96%
$6.18
CIFR
+1.64%
$15.17
SNAP
-0.23%
$8.56
IREN
-2.77%
$47.30
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
DNN
+0.80%
$2.51
ADD
-25.47%
$0.05
AMD
+0.40%
$248.97
DVLT
+14.27%
$1.75
SMCI
-7.43%
$35.09
WULF
-1.34%
$11.52
RIVN
-7.20%
$15.20
BMNR
-7.79%
$33.72
SRM
+53.27%
$10.30
MARA
-3.87%
$12.28
CRCL
+0.72%
$82.93
WBD
+3.74%
$22.97
APLT
-8.00%
$0.24
CLSK
-6.87%
$11.15
APLD
-12.68%
$23.06
ORCL
+4.04%
$226.37
GRAB
-1.88%
$5.43
CAN
-7.35%
$0.89
BTG
+0.73%
$4.13
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
MU
+5.42%
$249.80
PLTD
-2.10%
$6.76
XPON
-5.51%
$1.20
HOOD
+1.81%
$123.73
QUBT
+5.44%
$10.57
GPUS
-5.51%
$0.28
BBD
+1.09%
$3.70
PLTZ
-4.66%
$6.71
AMZN
-0.80%
$235.67
HIMS
+3.73%
$37.39
NBIS
-5.56%
$83.70
CSCO
+1.27%
$78.36
ABEV
+1.38%
$2.55
BABA
-4.50%
$152.64
KDLY
-6.80%
$0.62
NOK
-0.51%
$6.74
T
-0.64%
$25.58
IONQ
+4.93%
$47.64
SOUN
+0.12%
$12.23
AFMD
-34.94%
$0.18
BTBT
-2.92%
$2.44
RGTZ
-3.43%
$27.17
JD
-4.50%
$29.32
RIG
+0.37%
$4.02
GOOGL
-0.35%
$277.58
BURU
-1.60%
$0.25
RIOT
+2.83%
$14.27
DEFT
-12.06%
$1.27
BAC
-0.14%
$52.79
BTE
-0.47%
$3.12
BCG
+32.28%
$1.88
QS
+1.14%
$13.72
DFLI
+6.85%
$0.82
AAL
-1.91%
$12.81
RXRX
-2.23%
$4.23
PCG
-0.95%
$16.65
LYFT
-3.13%
$23.80
BE
+8.23%
$112.07
LAES
-7.21%
$4.51
VZ
-0.06%
$41.08
PSNY
-14.57%
$0.53
KLG
-9.05%
$13.35
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.